Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07583186

Maternal Intake of Eggs and Infant Neurodevelopment

The fetal brain requires DHA, choline, lutein, and zeaxanthin (L/Z) for development, dependent on maternal intake during pregnancy. However, many pregnant women do not meet daily requirements through diet or prenatal vitamins. Egg yolks are rich in choline, and women who consume eggs daily are more likely to meet the adequate intake of 450 mg/day. A recent study by Christifano et al. found that maternal egg and neuroprotective nutrient intake predicted neurodevelopment at 32 and 36 weeks of gestation. This study aims to determine if fetal neurodevelopment is enhanced among women who consume a prenatal diet emphasizing egg consumption (EGG) versus a healthy prenatal diet education control group (HPD). Women between 12-20 weeks' gestation will be randomized into EGG and HPD groups. The EGG group will receive education on the importance of prenatal choline and egg consumption and be encouraged to consume 10-14 eggs per week. The HPD group will receive education on a healthy prenatal diet. Both groups will be encouraged to take a DHA supplement, and dietary intake of choline, L/Z, and DHA will be collected. Fetal heart rate variability will be measured at 36 weeks gestation and infant EEGs will be conducted postnatally to examine brain function. Increasing prenatal egg consumption is both economical and feasible to boost prenatal choline intake, promote offspring neurodevelopment, and guide prenatal dietary recommendations.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

The University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location status: Recruiting

Location contact

Alexandra Brown, PhD

SUB_INVESTIGATOR

Danielle Christifano, PhD

PRINCIPAL_INVESTIGATOR

Ke Liao, PhD

SUB_INVESTIGATOR

Lara Bennett, MS

CONTACT

913-945-9149

Nicole Mathis, MS

CONTACT

913-588-1906

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant females ≥18 years of age
  • 12 to 20-weeks' gestation at enrollment
  • No serious illnesses likely to confound study outcomes
  • Consuming 3 eggs/week or less at enrollment and willing to increase consumption during the study
  • Singleton gestation
  • Available by telephone and text

Exclusion criteria

  • Less than 18 years at enrollment
  • Gestational age at enrollment <12 or >20 weeks
  • Any serious illness likely to confound study outcomes
  • Consuming more than 3 eggs per week at enrollment
  • Unable/unwilling to consume eggs until delivery or egg allergy
  • Expecting multiple infants
  • No access to telephone or text

Treatment and study plan

Egg Supplementation

Dietary Supplement

Encouraged to consume 10-14 eggs per week.

Healthy Prenatal Diet

Dietary Supplement

Educated on standard healthy prenatal diet and encouraged to follow recommendations.

Primary outcomes

  1. Fetal neurodevelopment as indexed by heart rate variability (HRV)

    Time frame: 36 weeks gestational age

    Group comparisons will be made between time-domain metrics of fetal HRV (SDNN, RMSSD) between those in EEG vs. HPD groups using a dedicated fetal heart rate monitor.

Secondary outcomes

  1. Fetal neurodevelopment as indexed by heart rate variability (HRV)

    Time frame: 36 weeks gestational age

    Relationship between intake of maternal neuroprotective nutrients, including choline, docosahexaenoic acid (DHA), lutein and zeaxanthin (L/Z) as measured by the Diet History Questionnaire-III and offspring neurodevelopment at 36 weeks gestation (fetal HRV).

  2. Infant neurodevelopment as indexed by event-related potentials (ERP)

    Time frame: 1 month postnatal age

    Brain neurophysiology will be measured at 1 month of age. Assessments of band-limited spectral power during resting-state will be assessed. Event-related potentials (ERP) to auditory stimuli will be recorded. Group comparisons will be made between measures of resting state spectral power and auditory ERP components.

  3. Infant neurodevelopment as indexed by event-related potentials (ERP)

    Time frame: 1 month postnatal age

    Relationship between intake of maternal neuroprotective nutrients, including choline, docosahexaenoic acid (DHA), lutein and zeaxanthin (L/Z) as measured by the Diet History Questionnaire-III and offspring neurodevelopment at 1 month postnatal age (infant ERP).

Study contacts

Contact information is provided by the study sponsor or research team.

Lara Bennett, MS

CONTACT

[email protected]

913-945-9149

Nicole Mathis, MS

CONTACT

[email protected]

913-588-1906

Sponsors and collaborators

Lead sponsor

University of Kansas Medical Center

Other

Registry information

Acronym: MIND

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 13, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.